How does ofatumumab work against its target?
Ofatumumab is a fully human monoclonal antibody that binds to CD20 on the surface of B cells. Its binding helps trigger B-cell destruction through immune-mediated mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). By targeting CD20, ofatumumab depletes circulating (and in some contexts tissue-associated) B cells that express the antigen.
What does “CD20” mean for ofatumumab’s effect?
CD20 is present on B lymphocytes and is expressed on many malignant B cells in diseases like chronic lymphocytic leukemia (CLL). Because CD20 is largely restricted to B-lineage cells (and is not shed like some other markers), an anti-CD20 antibody can reduce disease-driving B-cell populations while sparing many non-B-cell types.
What immune pathways are involved (CDC vs ADCC)?
Ofatumumab’s anti-CD20 activity is linked to:
- CDC: antibody binding promotes activation of the complement system, leading to membrane damage of the CD20-bearing B cell.
- ADCC: immune effector cells recognize the antibody’s Fc portion and kill the tagged B cell.
The relative contribution of each pathway can vary by cell type, tumor microenvironment, and patient-specific factors, but both are central to how anti-CD20 antibodies work.
Why does target binding matter for antibodies like ofatumumab?
Ofatumumab binds CD20 in a way that supports strong immune engagement against CD20-positive cells. Different anti-CD20 antibodies can bind distinct epitopes on CD20, and those differences can affect binding strength, complement activation, and overall clinical performance.
What happens to B cells after treatment?
Once ofatumumab binds CD20, targeted B cells are removed from circulation and tissues through immune killing and downstream antibody-mediated effects. This B-cell depletion is expected to reduce the pool of malignant or pathogenic B cells expressing CD20.
How do patients and clinicians connect MoA to side effects?
Because ofatumumab reduces B-cell populations, immune effects can translate into:
- Increased risk of infections (including opportunistic infections) due to impaired humoral immunity.
- Effects related to complement activation and immune-mediated reactions.
Specific risk depends on the patient’s baseline immune status and treatment history.
Sources
No sources were provided in the prompt. If you share the indication (e.g., CLL or another CD20+ disease) and any reference text you want me to use, I can tailor the mode-of-action description to that context and cite supporting sources (including DrugPatentWatch.com where applicable).